Abstracts tagged "treatment"

Abstract Number: 1266 • 2012 ACR/ARHP Annual Meeting
Evaluation of Metabolic Syndrome in 97 Patients with Rheumatoid Arthritis
Fernanda G. G Chaer¹, Juliana Lucena², Rogerio Castro Reis³, Fabiola Brasil², Murilo Melo⁴, Amanda Callegari⁵ and Branca Souza⁵, ¹Reumatologia, Santa Casa de Sao Paulo, São Paulo, Brazil, ²Reumatologia, Irmandade da Santa Casa de Misericordia de Sao Paulo, São Paulo, Brazil, ³Reumatologia, Santa Casa de Sao Paulo, São Paulo, Brazil, ⁴Irmandade da Santa Casa de Misericordia de São Paulo, São Paulo, Brazil, ⁵Reumatologia, Irmandade da Santa Casa de Misericordia de São Paulo, São Paulo, Brazil
Background/Purpose: Rheumatoid arthritis (RA) is an independent risk factor for cardiovascular disease (CVD), which is the leading cause of death in this group. Thus, the…
Abstract Number: 488 • 2012 ACR/ARHP Annual Meeting
Patient Preferences for Biologic Treatments in Rheumatoid Arthritis
Beenish Nafees¹, Andrew Lloyd¹, Carol L. Gaich², Julie Birt² and Rodney A. Hughes³, ¹Late Phase & Outcomes Research, Oxford Outcomes, Oxford, United Kingdom, ²Global Health Outcomes, Eli Lilly and Company, Indianapolis, IN, ³Rheumatology, St. Peters Hospital, Chertsey Surrey, United Kingdom
Background/Purpose: Patients with rheumatoid arthritis (RA) and their physicians face a range of treatment choices. The treatments that patients receive should be driven partly by…
Abstract Number: L11 • 2012 ACR/ARHP Annual Meeting
First in Patient Study of Anti-GM-CSF Monoclonal Antibody (MOR103) in Active Rheumatoid Arthritis: Results of a Phase 1b/2a Randomized, Double-Blind, Placebo-Controlled Trial
Frank Behrens¹, Mikkel Ostergaard², Rumen Stoilov³, Piotr Wiland⁴, Thomas W. Huizinga⁵, Vadym Y. Berenfus⁶, Paul-Peter Tak⁷, Stoyanka Vladeva⁸, Juergen Rech⁹, Andrea Rubbert-Roth¹⁰, Mariusz Korkosz¹¹, Dmitriy Rekalov¹², Igor A. Zupanets¹³, Bo J. Ejbjerg¹⁴, Jens Geiseler¹⁵, Julia Fresenius¹⁵, Roman P. Korolkiewicz¹⁶, Arndt J. Schottelius¹⁶ and Harald Burkhardt¹, ¹CIRI /Div. of Rheumatology, Goethe-University, Frankfurt/Main, Germany, ²Copenhagen Center for Arthritis Research, Copenhagen University Hospital at Glostrup, Glostrup, Denmark, ³Clinic of rheumatology, University Hospital (MHAT) St. Ivan Rilski, Sofia, Bulgaria, ⁴Department of Rheumatology, Medical University of Wroclaw, Wroclaw, Poland, ⁵Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁶Occupational Diseases, Regional Clinical Hospital, Donetsk, Ukraine, ⁷Academic Medical Center / currently also GlaxoSmithKline, Amsterdam, Netherlands, ⁸Second Internal Clinic UMHAT Stara Zagora, Stara Zagora, Bulgaria, ⁹Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, ¹⁰Internal Medicine I, University of Cologne, Cologne, Germany, ¹¹Malopolskie Centrum Medyczne, Krakow, Poland, ¹²Department of Internal Diseases, Zaporizhzhia Regional Hospital, Zaporozhe, Ukraine, ¹³Clinical and Diagnostics Centre of National Pharmaceutical University MOH of Ukraine, Kharkiv, Ukraine, ¹⁴Slagelse Sygehus, Slagelse, Denmark, ¹⁵Asklepios Clinic Munich-Gauting, Gauting, Germany, ¹⁶Development, MorphoSys AG, Martinsried/Planegg, Germany
Background/Purpose: MOR103, a human mAb targeting GM-CSF, is being evaluated for treatment of rheumatoid arthritis (RA). Pre-clinical studies on cytokine function and investigations in experimental…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].